CNS Pharmaceuticals Q3 2026: $10.0M Nine-Month Loss, $17.2M Cash, Material Weakness Persists
CNSP sits 57% above its 52-week low of $1.9 on elevated volume (1.8× avg).
Summary
CNS Pharmaceuticals posted a $10.0M nine-month net loss and $11.0M operating cash burn, ending September with $17.2M in cash that management says funds operations beyond twelve months. The company still carries a material weakness in internal controls and 9.14M unexercised pre-funded warrants.
Key Events · Earnings and Guidance · CNSP
-
Q3 Net Loss $2.5M; Nine-Month Loss $10.0M
Net loss was $2.499M for Q3 2026 versus $3.218M a year earlier, and $10.024M for the nine months versus $9.895M in 2025. R&D fell to $5.636M from $6.607M as the Berubicin trial wound down, while G&A rose to $4.705M from $3.393M.
-
Cash $17.2M After $22.5M May Placement
Cash and equivalents were $17.2M at September 30, 2026, up from $7.2M at December 31, 2025, after the May 2026 private placement of 650,000 shares at $2.30 and 9,143,479 pre-funded warrants at $2.299 raised $22.5M gross and $20.7M net.
-
Operating Cash Burn $11.0M Year-to-Date
Net cash used in operating activities was $10.961M for the nine months ended September 30, 2026, versus $10.759M a year earlier, funded by $21.208M of net equity proceeds.
-
Material Weakness Persists; Controls Ineffective
Management concluded disclosure controls were ineffective at September 30, 2026 because of material weaknesses, primarily lack of segregation of duties from limited personnel. The Berubicin CRO-related contributing factor was eliminated as the study closed out, but the segregation-of-duties weakness remains.
Analysis · CNSP · Life Sciences
CNS burned $11.0M of operating cash in the first nine months of 2026 against a $10.0M net loss, and the $22.5M May private placement left it with $17.2M of cash at September 30 — enough, management says, to fund operations beyond twelve months. The offset: no revenue, an accumulated deficit of $110.3M, and a material weakness in internal controls that keeps disclosure controls ineffective because of a lack of segregation of duties. The 9.14M pre-funded warrants from the May placement remain unexercised and sit in the diluted share count, so the fully diluted share base is far larger than the 1.48M shares outstanding. Management's stated plan is to acquire rights to a new asset by the end of 2026, which is the event that would change the story.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNSP was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $1.90 to $10.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.